Genome Biologics
Genome Biologics
  • Home
  • Therapies
  • Technology
  • Publications
  • Press
  • Our team
  • Horizon 2020
  • Contact us
  • Mehr
    • Home
    • Therapies
    • Technology
    • Publications
    • Press
    • Our team
    • Horizon 2020
    • Contact us
  • Home
  • Therapies
  • Technology
  • Publications
  • Press
  • Our team
  • Horizon 2020
  • Contact us

EIC Horizon 2020

Genome Biologics

This project received funding from the European Union Horizon 2020 research and innovation programme under Grant Agreement No 822455.

About SME Instrument

SME Instrument is part of the Horizon 2020 work programme that funds high potential innovations in the EU. This highly competitive fund is only offered to SMEs which fall under the European Innovation Council (EIC) SME definition. SME Instrument offers Europe's brightest and boldest innovators the funding for breakthrough ideas with the potential to create entirely new markets or revolutionise existing ones.


Please click here to learn more about funding opportunities through the SME Instrument.

SME Instrument

SME Instrument Phase 2 Award

Project Overview


Recent advances in genomics, molecular science, and big data are changing the way we define and target diseases, but drug discovery is still a time-consuming, expensive and risky process. Genome Biologics provides a unique combination of tools – GENIMAPS and GENISYST – to provide an  integrated platform, with a disruptive effect on the time, cost and risk  of drug discovery and pre-clinical trial development.


GENISYST uses a unique transgenic methodology to allow up to 50 genes to be  expressed in a pre-clinical model, directly in target tissue, without affecting the genome.The toolkit reduces the time to prepare  pre-clinical models, and the cost of drug discovery and pre-clinical  trials, by an order of magnitude. The impact of this is cheaper, more rapidly developed, drugs, with a greater target to market success rate. 


GENIMAPS combines big data, Ai and a unique multiomics approach to make rapid and precise matches between disease indicators and compound behaviours,  allow rapid identification of targets, genetic expression, and compound matches. As well as precision medicine, GENIMAPS also allows the rapid evaluation of an existing pipeline, allowing repositioning opportunities for FDA approved assets (or orphan drugs) – increasing the return on public and private investment.

Project Report_Genome Biologics_H2020 SME Instrument (pdf)Herunterladen

SME Instrument Award Press Release

Genome Biologics wins prestigious Horizon 2020 SME Instrument grant

Genome Biologics_H2020 SME Instrument (pdf)Herunterladen
Genome Biologics_EIC Accelerator 2021 (pdf)Herunterladen

Copyright © 2023 Genome Biologics – Alle Rechte vorbehalten.

  • Privacy Policy

This site uses cookies.

We use cookies to analyze website traffic and to optimize your user experience for this website. If you accept cookies, your data will be merged with that of other users.

ACCEPT